Phase 1
Completed N=12
MK-2060 and Clopidogrel Co-administration Safety and Tolerability Study in Participants With End-Stage Renal Disease (ESRD) (MK-2060-008)
End Stage Renal Disease · Kidney Failure, Chronic
Source: ClinicalTrials.gov NCT05335005 ↗
Enrolled (actual)
12
Serious AEs
12.5%
Results posted
Oct 2024
Primary outcomePrimary: Number of Participants Who Experience One or More Bleeding Related Adverse Events (AE) — 0 Participants
Summary
MK-2060 is being developed for prevention of thrombotic complications in end-stage renal disease (ESRD). The purpose of this study is to conduct a preliminary evaluation of the safety and tolerability of MK-2060 treatment in combination with a commonly used P2Y12 receptor inhibitor, clopidogrel, in ESRD patients.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants Who Experience One or More Bleeding Related Adverse Events (AE) |
— | — |
| PRIMARY Number of Participants Who Experience One or More AEs |
6 | — |
| PRIMARY Number of Participants Who Discontinue Study Intervention Due to an AE |
— | — |
| SECONDARY Area Under the Concentration-Time Curve From 0 to 168 Hours (AUC0-168) of MK-2060 |
2040; 9060 | — |
| SECONDARY Maximum Plasma Concentration (Cmax) of MK-2060 |
29.7; 87.6 | — |
| SECONDARY Plasma Concentration at 168 Hours (C168) of MK-2060 |
43.1; 34.3 | — |
| SECONDARY Time to Maximum Plasma Concentration (Tmax) of MK-2060 |
1.03; 1.07 | — |
| SECONDARY Terminal Half Life (t1/2) of MK-2060 |
402 | — |
| SECONDARY Clearance at Steady State (CLss) of MK-2060 |
0.0170 | — |
| SECONDARY Apparent Volume of Distribution at Steady State (Vss) of MK-2060 |
6.34 | — |
| SECONDARY Time to Hemostasis Following MK-2060 Treatment |
11.0 | — |
Eligibility Criteria
Inclusion Criteria
- Has End-Stage Renal Disease (ESRD) maintained on stable outpatient hemodialysis (HD) regimen at a healthcare center for > 3 months prior to dosing.
- On HD regimen at least 3 times per week for a minimum of 3 hours per dialysis session, using a complication-free well-maintained AV fistula or AV graft.
- Is taking clopidogrel for a minimum of 2 weeks prior to the first dosing of MK-2060 administration.
- Has a Body Mass Index (BMI) ≥ 18 and ≤ 45 kg/m^2.
Exclusion Criteria
- History of cancer (malignancy), including adenocarcinoma, except adequately treated nonmelanomatous skin carcinoma or carcinoma in situ of the cervix or other malignancies that have been successfully treated with appropriate follow up.
- Has a history of deep vein thrombosis or pulmonary embolism.
- Has a history of gastrointestinal (GI) bleeding, duodenal polyps or gastric ulcer in the last 5 years or severe hemorrhoidal bleed in last 3 months prior to screening.
- Is positive for hepatitis B surface antigen or human immunodeficiency virus (HIV).
- Has ongoing anticoagulant therapy or antiplatelet therapy, not including clopidogrel. Intradialytic heparin is permitted.
Data sourced from ClinicalTrials.gov (NCT05335005). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.